| Description | BMS-817399 is an orally active antagonist of CCR1 with IC50s of binding affinity and chemotaxis inhibition potencies and can be used in studies about rheumatoid arthritis. |
| Target activity | CCR1:1 nM (IC50) |
| Synonyms | BMS817399 |
| molecular weight | 454 |
| Molecular formula | C23H36ClN3O4 |
| CAS | 1202400-18-7 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 55 mg/mL (121.14 mM) |
| References | 1. Chen H, et al. Moisture-Induced Amorphous Phase Separation of Amorphous Solid Dispersions: Molecular Mechanism, Microstructure, and Its Impact on Dissolution Performance. J Pharm Sci. 2018 Jan;107(1):317-326. 2. Khan JA, et al. Developing Adnectins that target SRC co-activator binding to PXR: a structural approach toward understanding promiscuity of PXR. J Mol Biol. 2015 Feb 27;427(4):924-42. 3. Santella JB 3rd, et al. Discovery of the CCR1 antagonist, BMS-817399, for the treatment of rheumatoid arthritis. J Med Chem. 2014;57(18):7550-7564. |